報價延遲最少15分鐘:2026/04/21 21:21 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
34.35 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-22.49/-8.27
|
|
企業價值
580.79M
|
| 資產負債 |
|
每股賬面淨值
-7.99
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
102.48M
|
|
每股收益
3.43
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. Company's wholly-owned product candidate is STRO-004, a single homogeneous ADC directed against tissue factor which are developing for the treatment of solid tumors. The company also pipeline contains STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others. |
